scholarly journals Effect of body mass index on pharmacokinetics of paclitaxel in patients with early breast cancer

2021 ◽  
Author(s):  
Vikram Gota ◽  
Manjunath Nookala ◽  
Avinash Bonda ◽  
Ashwin Karanam ◽  
Bharati Shriyan ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Body Mass Index ◽  
Body Mass ◽  
Early Breast Cancer

scholarly journals Association of body mass index and cardiotoxicity related to anthracyclines and trastuzumab in early breast cancer: French CANTO cohort study

PLoS Medicine ◽  
2019 ◽  
Vol 16 (12) ◽  
pp. e1002989 ◽  
Author(s):  
Elisé G. Kaboré ◽  
Charles Guenancia ◽  
Ines Vaz-Luis ◽  
Antonio Di Meglio ◽  
Barbara Pistilli ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Body Mass Index ◽  
Cohort Study ◽  
Body Mass ◽  
Early Breast Cancer

Body Mass Index and Hormone Receptor Status Influence Recurrence Risk in HER2-Positive Early Breast Cancer Patients

2020 ◽  
Vol 20 (1) ◽  
pp. e89-e98 ◽  
Author(s):  
Luca Cantini ◽  
Mirco Pistelli ◽  
Filippo Merloni ◽  
Andrea Fontana ◽  
Ilaria Bertolini ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Body Mass Index ◽  
Cancer Patients ◽  
Body Mass ◽  
Early Breast Cancer ◽  
Hormone Receptor ◽  
Recurrence Risk ◽  
Hormone Receptor Status ◽  
Breast Cancer Patients ◽  
Her2 Positive

The prognostic impact of body mass index (BMI) in early breast cancer (BC) patients (pts)

2005 ◽  
Vol 23 (16_suppl) ◽  
pp. 882-882
Author(s):  
M. S. Iyikesici ◽  
U. Kefeli ◽  
G. Basaran ◽  
F. Dane ◽  
M. Ekenel ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Body Mass Index ◽  
Body Mass ◽  
Early Breast Cancer ◽  
Prognostic Impact

Interaction between body mass index and bone turnover during aromatase inhibition: Evidence from the letrozole (L), exemestane (E), and anastrozole (A) pharmacodynamics (LEAP) trial

2007 ◽  
Vol 25 (18_suppl) ◽  
pp. 560-560 ◽  
Author(s):  
E. McCloskey ◽  
R. Hannon ◽  
G. Lakner ◽  
G. Clack ◽  
A. Miyamoto ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Body Mass Index ◽  
Bone Resorption ◽  
Bone Turnover ◽  
Postmenopausal Women ◽  
Body Mass ◽  
Early Breast Cancer ◽  
Aromatase Inhibitors ◽  
Baseline Bmi ◽  
High Bmi

560 Background: High body mass index (BMI) protects against postmenopausal osteoporotic fracture, mediated in part by higher endogenous levels of oestradiol. Third-generation aromatase inhibitors (AIs) show superior efficacy and tolerability than tamoxifen in the adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer. We examined the interactions between BMI and bone turnover during treatment with 3 aromatase inhibitors in the LEAP trial, an open, randomized, pharmacodynamic study in postmenopausal women. Methods: Healthy volunteers from the UK and Hungary with normal bone density and BMI between 18 and 34 kg/m2 were randomized to receive A (1 mg/day), L (2.5 mg/day), or E (25 mg/day) orally, once daily for 24 weeks. Effects on bone resorption (log transformed serum C-telopeptide crosslinks, CTX) and bone formation (bone alkaline phosphatase and propeptide of type I procollagen, PINP) were compared. Changes in biochemical markers of bone resorption and formation during treatment were all statistically inter- correlated (p<0.01) with no notable differences between the 3 agents studied, so that the groups were pooled for analysis. Spearman correlation coefficients and the p-values were computed. Results: A total of 90 participants were evaluable at baseline and at 24 weeks (29 A, 29 L, 32 E). As expected, baseline BMI correlated with pre-treatment circulating endogenous oestradiol (r=0.28, p=0.007) and both BMI and oestradiol negatively correlated with baseline serum CTX (r=-0.32, p=0.0025 and r=-0.35, p=0.0007 respectively) and PINP (r=-0.30, p=0.004 and r=-0.26, p=0.016 respectively). Baseline BMI and oestradiol were significantly correlated with the increase in serum CTX (r=0.26, p=0.015 and r=0.23, p=0.032 respectively) and BMI also correlated significantly with the increase in serum PINP (r=0.23, p=0.030). Conclusions: Steroidal and non-steroidal AIs increase bone turnover with the greatest increase in women with high BMI and higher oestradiol levels at baseline. As increased bone turnover is an independent risk factor for fracture, a high BMI may not confer a reduced fracture risk in the setting of AI use in early breast cancer. No significant financial relationships to disclose.

Effect of body mass index on metastatic pattern in early breast cancer patients.

2014 ◽  
Vol 32 (15_suppl) ◽  
pp. e11553-e11553
Author(s):  
Ozan Yazici ◽  
Sercan Aksoy ◽  
Mehmet Ali Nahit Sendur ◽  
Nuriye Özdemir ◽  
Nurullah Zengin ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Body Mass Index ◽  
Cancer Patients ◽  
Body Mass ◽  
Early Breast Cancer ◽  
Breast Cancer Patients ◽  
Metastatic Pattern
Sign in / Sign up

Export Citation Format

Share Document